Zydus Lifesciences (NSE:ZYDUSLIFE) 3-Year Book Growth Rate : 15.80% (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences 3-Year Book Growth Rate?

Zydus Lifesciences's Book Value per Share for the quarter that ended in Mar. 2024 was ₹197.07.

During the past 12 months, Zydus Lifesciences's average Book Value per Share Growth Rate was 13.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was 15.80% per year. During the past 5 years, the average Book Value per Share Growth Rate was 16.00% per year. During the past 10 years, the average Book Value per Share Growth Rate was 18.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Zydus Lifesciences was 27.90% per year. The lowest was -6.90% per year. And the median was 19.80% per year.

Competitive Comparison of Zydus Lifesciences's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zydus Lifesciences's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's 3-Year Book Growth Rate falls into.

Zydus Lifesciences 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Zydus Lifesciences (NSE:ZYDUSLIFE) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Zydus Lifesciences 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences (NSE:ZYDUSLIFE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (NSE:ZYDUSLIFE) » Definitions » 3-Year Book Growth Rate

Traded in Other Exchanges

532321:India

Address

Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481

Website

https://www.zyduslife.com

Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (NSE:ZYDUSLIFE) Headlines

No Headlines